Evidence map›Paper›PMID 39443355›Full record

ArticleClinical and experimental medicine2024

SASS6 promotes tumor proliferation and is associated with TP53 and immune infiltration in lung adenocarcinoma.

Zihao Li, Lingyun He, Jiayi Li, Jing Qian, Zuotao Wu, Yongjie Zhu, Ting Zhuo, Jusen Nong, Honghua Liang, Hua Zheng and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zihao Li *Department of Thoracic Surgery, Liuzhou People's Hospital affiliated to Guangxi Medical University, Liuzhou, Guangxi, China.
Lingyun He *Department of Thoracic Surgery, Liuzhou People's Hospital affiliated to Guangxi Medical University, Liuzhou, Guangxi, China.
Jiayi Li *Department of Nephrology, Liuzhou People's Hospital affiliated to Guangxi Medical University, Liuzhou, Guangxi, China.
Jing QianDepartment of Cardio-Thoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Zuotao WuDepartment of Cardio-Thoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Yongjie ZhuDepartment of Cardio-Thoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Ting ZhuoDepartment of Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Jusen NongDepartment of Pediatric Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Honghua LiangDepartment of Thoracic Surgery, Liuzhou People's Hospital affiliated to Guangxi Medical University, Liuzhou, Guangxi, China.
Hua ZhengDepartment of Thoracic Surgery, Liuzhou People's Hospital affiliated to Guangxi Medical University, Liuzhou, Guangxi, China.
Weijia HuangDepartment of Thoracic Surgery, Liuzhou People's Hospital affiliated to Guangxi Medical University, Liuzhou, Guangxi, China.
Julu HuangDepartment of Medical Oncology, Liuzhou People's Hospital affiliated to Guangxi Medical University, Liuzhou, Guangxi, China. huangjulu@stu.gxmu.edu.cn.
Jianbin CaoDepartment of Thoracic Surgery, Liuzhou People's Hospital affiliated to Guangxi Medical University, Liuzhou, Guangxi, China. 18907722555@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most common type of non-small cell lung cancer is lung adenocarcinoma (LUAD), which is characterized by high morbidity and poor survival. Up-regulation of SASS6 expression can lead to the progression of various malignant tumors. However, there are no relevant studies on the role of SASS6 in LUAD. SASS6 was highly expressed in most tumors, reflecting a good diagnostic value, and its overexpression in LUAD indicated discouraging overall prognosis. Functional enrichment analysis suggested that SASS6 was associated with cell cycle in LUAD. In addition, patients with high SASS6 expression had worse immune infiltration, but higher TMB and immune checkpoint, and higher sensitivity to multiple targeted drugs such as osimertinib. Cell experiments confirmed that knockdown of SASS6 could inhibit the viability of tumor cells.SASS6 has important value in the diagnosis of cancer. In particular, SASS6 is a crucial factor in the progression of LUAD, and has important clinical value, especially in the diagnosis, prognosis and treatment.

Indexed as

Adenocarcinoma of LungCell Cycle ProteinsCell ProliferationLung NeoplasmsTumor Suppressor Protein p53AcrylamidesAniline CompoundsBiomarkers, TumorCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansIndolesMaleMiddle AgedPrognosisAcrylamidesAniline CompoundsBiomarkers, TumorCell Cycle ProteinsIndolesosimertinibPyrimidinesSASS6 protein, humanTP53 protein, humanTumor Suppressor Protein p53Cell cycleImmune infiltrationLung adenocarcinomaPrognosisSASS6

Identifiers

PMID39443355
PMCPMC11499408

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.